Navidea Biopharma (NAVB) Reports Q4 Loss of $0.02

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.02), versus ($0.04) reported last year. Revenue for the quarter came in at $119.32 thousand, versus $391.49 thousand reported last year.

“Navidea had a productive quarter as we advanced the business and our novel imaging pipeline,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. “While we had many successes this past quarter, we will continue to work hard to advance the science and seek the go ahead from the FDA to commence our pivotal RA diagnostic trials. Our newly reconstituted board and the addition of our new Chief Medical Officer have reinvigorated our efforts to make this company a success.”

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Neuronetics promotes CTO to EVP, General Manager of Greenbrook